A systematic review of the role bisphosphonates in metastatic disease

Health Technology Assessment

Volumn 8, Issue 4, 2004, Pages

  Ross, J R ^a   Saunders, Y ^a   Edmonds, P M ^b   Patel, S ^c   Wonderling, D ^d   Normand, C ^d   Broadley, K ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRONAT; ALENDRONIC ACID; ASCREDAR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; FUROSEMIDE; GALLIUM NITRATE; HYDROCORTISONE; IBANDRONIC ACID; LORON; LYTOS; MITHRAMYCIN; NERIDRONIC ACID; OCTREOTIDE; OLPADRONIC ACID; OSTEODIDRONEL; OSTEUM; PAMIDRONIC ACID; PHOSPHATE; RISEDRONIC ACID; SALCATONIN; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ABDOMINAL CRAMP; ADVANCED CANCER; ANEMIA; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; EARLY CANCER; EPISCLERITIS; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MORBIDITY; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; ORTHOPEDIC SURGERY; OSTEOMALACIA; REVIEW; RISK ASSESSMENT; SCLERITIS; SIDE EFFECT; SKIN MANIFESTATION; SPINAL CORD COMPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; UVEITIS; VERTEBRA FRACTURE;

EID: 1442351128     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta8040     Document Type: Review

References (335)

1. Blomen LJ. History of bisphosphonates: discovery and history of non-medical uses of bisphosphonates. In Bijvoet OL, Fleisch H, Canfield RE, Russell RG, editors. Bisphosphonate on bones. Amsterdam: Elsevier, 1995. pp. 111-24.
2. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962;203:671-5.
3. Fleisch H, Russell RG, Bisaz S. Influence of pyrophosphate on the transformation of amorphous to crystalline calcium phosphate. Berlin: Springer, 1968. pp. 49-59.
4. Fleisch H, Russell RG, Bisaz S. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate invitro and invivo. Calcif Tissue Res 1968;2:49-59.
5. Fleisch H. Bisphosphonates: mechanism of action. Endocrine Rev 1998;9:80-100.
6. Francis M, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in-vitro and pathological calcification in-vivo. Science 1969;165:1264-6.
7. Fleisch H, Russell RG, Francis M. Diphosphonates inhibit hydroxyapatite dissolution in-vitro and bone resorption in tissue culture and in-vivo. Science 1969;165:1262-4.
8. Russell RG, Rogers M, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999; 14( Suppl 2):53-65.
9. Jung A, Bisaz S, Fleisch H. The binding of pyophosphate and two diphosphonates by hydroxyappatite crystals. Calcif Tissue Res 1973;11:269-80.
10. Fleisch H. Bisphosphonates - preclinical. In Fleisch H, editor. Bisphosphonates in bone disease; from the laboratory to the patient. London: Parthenon, 1995. pp. 31-65.
11. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-44.
12. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999;24 (5 Suppl):73s-79s.
13. Yakatan GJ, Poyner WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982; 31:402-10.
14. Recker RR, Hassing GS, Lau JR, Saville PD. The hyperphosphatemic effect of disodium ethane-1-hydroxy-1,1-diphosphonates: renal handling of phosphorus and the renal response to parathyroid hormone. J Lab Clin Med 1973;81:258-66.
15. Francis MD, Martodam RR. Chemical, biochemical and medicinal properties of the diphosphonates. In Hilderbrand JD, editor. The role of bisphosphonates in living systems. Boca Raton, FL: CRC Press, 2001. pp. 55-96.
16. Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41:289-318.
17. Barnett B, Stickland L. Structure of disodium dihydrogen 1-hydroxyethylidenediphosphonate tetrahydrate: a bone growth regulator. Acta Crystallogra B 1979;35:1212-14.
18. Coleman RE, Purohit OP, Vinholes J. New roles for bisphosphonates in cancer therapy. Prog Palliative Care 1996;4:39-43.
19. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996;14:158-70.
20. Kanis J, McCloskey E. The use of clodronate in disorders of calcium and skeletal metabolism. In: Lomax P, Vessel E, editors. Progress in basic and clinical pharmacology. Basel: Karger, 1990. pp. 89-136.
21. Lufkin EG, Argueta R, Whittaker MD, Cameron AL, Wong VH, Egan KS, et al. Pamidronate: an unrecognised problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.
22. Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-90.
23. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT. Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease. Lancet 1984;i:821-4.
24. Mian M, Beghe F, Caprio A, Aloj R, Bertelli A. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol Res 1991; ii:107-14.
25. Siris ES. Bisphosphonates and iritis. Lancet 1993; 341:436.
26. Ghose K, Waterworth R, Trolove P, Highton J. Uveitis associated with Pamidronate. Aust NZ J Med 1994;24:320.
27. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Opthalmol 1994;118:220-4.
28. Fleisch H, Russell RG, Bisaz S, Muhlvauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970; 1:12-18.
29. Francis MD. The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 1969; 3:151-62.
30. Hanson N, Felix R, Bisaz S, Fleisch H. Aggregation of hydroxyapatite crystals. Biochim Biophys Acta 1976;451:549-59.
31. Luckman SP, Hughes DE, Coxon FP, Russell RG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
32. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, et al. Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-76.
33. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
34. Cancer Research Campaign. Cancer statistics: mortality - UK. London: Cancer Research Campaign, 2001. pp. 1-6.
35. Healey JH, Brown HK. Complications of bone metastases. Surgical management. Cancer 2000; 88:2940-51.
36. Coleman RE. Skeletal complications of malignancy. Cancer (Suppl) 1997;80:1588-94.
37. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone 1995;17 (2 Suppl): 101S-105S.
38. Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer 2000; 88 (12 Suppl): 33022-32.
39. Souhami R, Tobias J, editors. Breast cancer. In Cancer and its management. Oxford: Blackwell Science, 1998. pp. 216-34.
40. Bishop HM, Cameron DA, Coleman R, Davies AM, Dewar JA, Evans A, et al. British Association of Surgical Oncology Guidelines. Eur J Surg Oncol 1999;25:3-23.
41. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
42. In Souhami R, Tobias J, editors. Genitourinary cancer. Cancer and its management. Oxford: Blackwell Science, 1998. pp. 308-33.
43. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2001;88:2989-94.
44. Cancer Research Campaign. Cancer of the prostate. Factsheet 20. London: Cancer Research Campaign, 1994. pp. 1-5.
45. Souhami R, Tobias J, editors. Myeloma and other paraproteinaemias. In Cancer and its management. Oxford: Blackwell Science, 1998. pp. 470-82.
46. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
47. Twycross R. Biochemical syndromes. In Twycross R, editor. Symptom management in advanced cancer. Oxford: Radcliffe Medical Press, 1997. pp. 132-42.
48. Grill V, Rankin W, Martin TJ. Parathyroid hormone-related protein (PTHrP) and hypercalcaemia. Eur J Cancer 1998;34:222-9.
49. Ralston SH, Fogelman I, Gardner MD, Boyle IT. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia of malignancy. BMJ 1984;288:1405-8.
50. Wimalawansa SJ. Significance of plasma PTH-rP in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994;73:2223-30.
51. Siggaard-Andersen O, Thode J, Fogh-Andersen N. What is 'ionised calcium'? Scand J Clin Lab Invest 1983;43 (Suppl. 165):11-15.
52. Raman A. The calcium fractions of normal serum. Clin Biochem 1971;4:141-6.
53. Kanis JA, Yates AJ. Measuring serum calcium. BMJ 1985;290:728-9.
54. Davis JR, Heath DA. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. Br J Clin Pharmacol 1989;28:269-74.
55. Leading article. Correcting the calcium. BMJ 1977;1:598.
56. Ostenstad B, Andersen OK. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia. Acta Oncol 1992;31:861-4.
57. Gucalp R, Theriault R, Gill I, Madajewicz S, Chapman R, Navari R, et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994;154:1935-44.
58. Sawyer N, Newstead C, Drummond A, Cunningham J. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Miner 1990;9:121-8.
59. Raman A. The calcium fractions of normal serum. Clin Biochem 1971;4:141-6.
60. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268-76.
61. Portale AA. Blood calcium, phosphorus and magnesium. In Flavus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Richmond, VA: William Byrd, 1990. pp. 62-4.
62. Ralston SH, Thiebaud D, Herrmann Z, Steinhauer EU, Thurlimann B, Walls J, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 1997;75:295-300.
63. Wharrell RPJ, Murphy WK, Schulman P, O'Dwyer PJ, Heller G. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991;9:1467-75.
64. Payne RB, Carver ME, Morgan DB. Interpretation of serum total calcium: effects of adjustment for albumin concentration frequency of abnormal values and on detection of change in the individual. J Clin Pathol 1979;32:56-60.
65. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, et al. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993;11:1618-23.
66. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95:297-304.
67. Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992;10:134-42.
68. Body JJ, Magritte A, Seraj F, Sculier JP, Borkowski A. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. J Bone Min Res 1989;4:923-8.
69. Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer 1992;50:706-12.
70. Zysset E, Ammann P, Jenzer A, Gertz BJ, Portmann L, Rizzoli R, et al. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner 1992;18:237-49.
71. Berry EM, Gupta MM, Turner SJ, Burns RR. Variation in plasma calcium with induced changes in plasma specific gravity, total protein and albumin. BMJ 1973;4:640-3.
72. Payne R. Interpretation of serum calcium in patients with abnormal serum proteins. BMJ 1973;4:643-6.
73. Gardner MD, Dryburgh FJ, Fyffe JA, Jenkins AS. Predictive value of derived calcium figures based on the measurement of ionised calcium. Ann Clin Biochem 1981;18:106-9.
74. Payne RB, Carver ME, Morgan DB. Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 1979;32:56-60.
75. Bilezikian JP. Management of acute hypercalcaemia. N Engl J Med 1992; 326:1196-203.
76. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389-406.
77. Walls J, Bundred N, Howell A. Hypercalcaemia and bone resorption in malignancy. Clinical Orthop 1995;312:51-63.
78. Mundy GR. Hypercalcaemia associated with hematologic malignancies. In Mundy GR, editor. Calcium homeostasis: hypercalcaemia and hypocalcaemia. London: Martin Dunitz, 1990. pp. 100-15.
79. Grill V, Martin TJ. Hypercalcaemia of malignancy. Rev Endocr Metab Disord 2001;1:253-63.
80. Bajorunas DR. Clinical manifestations of cancer related hypercalcaemia. Semin Oncol 1990; 17 [2 (Suppl 5)]:16-25.
81. Kristensen B, Ejlertsen B, Mouridsen HT, Loft H. Survival in breast cancer patients after the first episode of hypercalcaemia. J Intern Med 1998; 244:189-98.
82. Elias EG, Reynoso G, Mittleman A. Control of hypercalcaemia with mithramycin. Ann Surg 1972;175:435.
83. Chisholm MA, Malloy AL, Taylor AT. Acute management of cancer related hypercalcaemia. Ann Pharmacother 1996;30:507-13.
84. Green L, Donehower RC. Hepatic toxicity of low doses of mithramycin in hypercalcaemia. Cancer Treat Rep 1984;68:1379-81.
85. Warrell RP, Israel R, Frisone M, Synder T, Gaynor JJ, Bockman RS. Gallium nitrate for acute treatment of cancer related hypercalcaemia. Ann Inter Med 1988;108:669-74.
86. Wineski LA. Salmon calcitonin in the acute management of hypercalcaemia. Calcif Tissue Int 1990; Suppl 46:S26-S30.
87. Harrison M, James N, Broadley K, Bloom SR, Armour R, Wimalawansa S, et al. Somatostatin analogue treatment for malignant hypercalcaemia. BMJ 1990;300:1313-14.
88. Riggs BL. Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? Bone 2000; 26:551-2.
89. Mundy GR. Hormonal factors which regulate bone resorption. In Mundy GR, Martin TJ, editors. Physiology and pharmacology of bone. New York: Springer, 1993. pp. 215-38.
90. Fleisch H. Bone and mineral metabolism. In Fleisch H, editor. Bisphosphonates in bone disease. From the laboratory to the patients. New York: Parthenon, 1995. pp. 11-28.
91. Manolagas SC. Role of cytokines in bone resorption. Bone 1995;17(2 Suppl):63s-67s.
92. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. N Engl J Med 1995; 332:305-11.
93. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996;11:150-9.
94. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotogerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
95. Simonet WS, Lecey DL, Dunstan C, Kelley M, Chang M, Luthy R, et al. Osteoprotogerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
96. Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C, et al. Osteoprotogerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
97. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88:2952-60.
98. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88:2919-26.
99. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;i:571-3.
100. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88:2892.
101. Orr FW, Lee J, Duivenvoorden WCM, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer 2000;88:2912-18.
102. Lemieux P, Harvey J, Guise TA, Dallas M, Oesterreich S, Yin JJ, et al. Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in-vivo. J Bone Miner Res 1999;14:1570-5.
103. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Overproduction of parathyroid hormone related peptide results in increased osteolytic skeletal metastases by prostate cancer cells in-vivo. Int J Cancer 1999;80:257-64.
104. Garrett IR. Bone destruction in cancer. Semin Oncol 1993;20 (3 Suppl 2):4-9.
105. Zhang Y, Fujita N, Oh-hara T, Morinaga Y, Nakagawa T, Yamada M, et al. Production of interleukin-11 in bone derived endothelial cells and its role in the formation of osteolytic bone metastases. Oncogene 1998;16:693-703.
106. Eilon G, Mundy GR. Direct resorption of bone by human breast cells in-vitro. Nature 1978;276:726-8.
107. Zhau HE, Li C, Chung LWK. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000;88:2995-3001.
108. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, et al. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998;78:1219-23.
109. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-71.
110. Engebraaten O, Fodstad O. Site specific experimental metastases patterns of two human breast cancer cell lines in nude rats. Int J Cancer 1999;82:219-25.
111. Kim RH, Sodek J. Transcription of the bone sialoprotein gene is stimulated by v-Src acting through an inverted CCAAT box. Cancer Res 1999;59:565-71.
112. Yoneda F, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000;88:2979-88.
113. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001;28 (2 Suppl 6):35-44.
114. Paterson AHG. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer 2000; 88:3038-46.
115. Galasko CS, Samuel AW, Rushton S, Lacey E. The effect of prostagladin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis. Br J Surg 1980;67:493-6.
116. Hall DG, Stoica G. Effect of bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 1994;9:221-30.
117. Krempien B. Morphological findings in bone metastasis, tumorosteopathy and anti-osteolytic therapy. In Diel IJ, Kaufman M, Bastert G, editors. Metastatic bone disease: fundamental and clinical aspects. Berlin: Springer, 1994. pp. 59-85.
118. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino F, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
119. Lee M, Fong E, Singer FR, Guenette R. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-8.
120. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-91.
121. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane Review). Cochrane Database Syst. rev. Oxford: Update Software, 2002; (2). CD002068.
122. BMA. British National Formulary. London: BMA and Royal Pharmaceutical Society of Great Britain, 2001. pp. 364-7.
123. Johnson IJ. Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK. Palliat Med 2001; 15:141-7.
124. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC III. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone 1991; 12 (Suppl 1):S37-S42.
125. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
126. Cook AM, Finlay IG, Edwards AGK, Hood K, Higginson IJ, Goodwin DM, et al. Efficiency of searching the grey literature in palliative care. J Pain Symptom Manage 2001;22:797-801.
127. StatXact 4.0.1. Cambridge, MA: Cytel Software, 2001.
128. Stata. Stata statistical software: release 7.0. College Station, TX: Stata, 2001.
129. Cochrane Library. Selection bias. In: Clarke M, Oxman AD, editors. Cochrane Reviewers Handbook 6.3 [updated June 2001]. The Cochrane Library, Issue 3. Oxford: Update Software. 2001, updated quarterly.
130. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289-93.
131. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcaemia of malignancy: a pooled analysis of two randomised, controlled clinical trials. J Clin Oncol 2001;19:558-67.
132. NHS Executive. Reference Costs 2000. Leeds: Department of Health, 2000.
133. NHS Executive. NHS Costing Manual. Leeds: Department of Health, 2000.
134. Beck J, Pauker S. The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
135. Lipton A, Theriault R, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000;88:1082-90.
136. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19(4C):3383-92.
137. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in Multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998;100: 317-25.
138. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
139. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17:846-54.
140. Dranitsaris G. Pamidronate for the prevention of skeletal related events in multiple myeloma. What does the public think it is worth? Int J Technol Assess Health Care 2001;15:108-22.
141. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-9.
142. Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC. Costs induced by hip fractures: a prospective controlled study in Belgium. Osteoporos Int 2000;11:373-80.
143. Brainsky A, Glick H, Lydick E, Epstein R, Fox KM, Hawkes W. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997;45:281-7.
144. Lane A. Direct costs of osteoporosis for New Zealand women. Pharmacoeconomics 1996;9:231-45.
145. Pientka L, Friedrich C. The costs of hip fracture in Germany; a prospective evaluation. Z Gerontol Geriatr 1999;32:326-32.
146. de Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Incremental cost of medical care after hip fracture and first vertebral fracture. Osteoporos Int 1999;10:66-72.
147. Dolan P, Torgeson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998;8:611-17.
148. Netten A, Rees T, Harrison G. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent and Canterbury, 2001.
149. Rimmer C. Establishing the cost of comfort. Effectiveness of pressure sore prevention. Prof Nurse 1992;810-15.
150. HM Treasury. Appraisal and evaluation in central government. 1997. Norwich: The Stationery Office.
151. NICE. Guidance for manufacturers and sponsors. London: National Institute for Clinical Excellence (NICE). 2001.
152. Weinstein NC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
153. Beusterien KM, Hill MC, Ackerman SJ, Zacker C. The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. Support Care Cancer 2001;9:169-76.
154. Bertheault-Cvitkovic F, Tubiana-Hulin M, Chevalier B, Clavel M, Rossy JF, Warrell RP. Gallium nitrate (GN) versus pamidronate (APD) for acute control of cancer-related hypercalcaemia (CRH): interim results of a randomised double-blind multi-national study (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995;14:A369.
155. Dodwell DJ, Howell A, Morton AR, Daley-Yates PT, Hoggarth CR. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgrad Med J 1992;68:434-9.
156. Fukumoto S, Matsumoto T, Takebe K, Onaya T, Eto S, Nawata H, et al. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. J Clin Endocrinol Metab 1994;79:165-70.
157. Gallacher SJ, Ralston SH, Fraser WD, Dryburgh FJ, Cowan RA, Logue FC, et al. A comparison of low versus high dose pamidronate in cancer-associated hypercalcemia. Bone Mineral 1991;15:249-56.
158. Hasling C, Charles P, Mosekilde L. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study. Euro J Clin Invest 1986;16:433-7.
159. Hasling C, Charles P, Mosekilde L. Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med 1987;82(2A):51-4.
160. Morton AR, Cantrill JA, Craig AE, Howell A, Davies M, Anderson DC. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. BMJ 1988;296:811-14.
161. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985;ii:907-10.
162. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989;ii:1180-2.
163. Rizzoli R, Thiebaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999;84:3545-50.
164. Rotstein S, Glas U, Eriksson M, Pfeiffer P, Hansen J, Soderqvist J, et al. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases - a prospective randomised placebo-controlled multicentre study. Eur J Cancer 1992;28A:890-3.
165. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997;15:131-8.
166. Warrell R, Mullane M, Bilezikian J, Edelstein M, Mallette M, Stepanavage M, et al. Treatment of cancer associated hypercalcaemia with alendronate sodium: a randomised double-blind comparison with etidronate (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997.
167. Wimalawansa SJ. Optimal frequency of administration of pamidronate in patients with hvpercalcaemia of malignancy. Clin Endocrinol 1994;41:591-15.
168. Atula S, Tahtela R, Nevalainen J, Pyikkanen L. Single IV infusion of clodronate 1500mg is effective in the treatment of hypercalcaemia of malignancy. Eur J Cancer 37 (Suppl 6), 2001;S354.
169. Canfield RE, Siris ES, Jacobs TP. Dichloromethylene diphosphate action in hematologic and other malignancies. Bone 1987;8(suppl. 1):557-562.
170. Chapuy MC, Meunier PJ, Alexandre CM, Vignon EP. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest 1980;65:1243-7.
171. Daragon A, Peyron R, Serrurier D, Deshayes P. Treatment of hypercalcemia of malignancy with intravenous aminohydroxypropylidene bisphosphonate. Results of a stratified, double-blind, randomized two-month dose-response study. Curr Ther Res Clin Exp 1991;50:10-21.
172. Delmas P, Chapuy MC, Vignon E, Briancon D, Charhon S, Meunier PJ. Dichloromethylene diphosphonate (C12MDP) treatment of hypercalcaemia produced from bone metastases. Nouv Presse Med 1982;11:1471-4.
173. Jung A, Chantraine A, Donath A, van Ouwenaller C, Turnill D, Mermillod B, et al. Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med 1983;308:1499-501.
174. Martinez ME, Pastrana P, Sanchez-Cabezudo MJ, Jariego C, Del Campo MT. Effect of clodronate on calcidiol serum levels in women with breast cancer. Calcif Tissue Int 1997;61:148-50.
175. Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 1983;74:421-32.
176. Murray R, Pitt P, Jerums G. A randomised trial of varying doses of aminohydroxypropylidene bisphosphonate (APD) in the treatment of hypercalcaemia of malignancy. Seventeenth annual scientific meeting, Clinical Oncology Society of Australia, 1990; IS28.
177. Pecherstorfer M, Steinhauer EU, Pawsev S. Ibandronic acid is more effective than pamidronate in lowering serum calcium in patients with severe hypercalcaemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calciums. Results of a randomised, open-label, comparative study. Proc Am Soc Clin Oncol 2001; 20:abstract 1535.
178. Pecherstorfer M, Steinhauer EU, Pawsey S. Ibandronic acid is more effective than pamidronate in lowering serum calcium in patients with severe hypercalcaemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calciums. Results of a randomised, open-label, comparative study. Proc Am Soc Clin Oncol 2001; 20;abs 1535
179. Ralston SH, Alzaid AA, Gallacher SJ, Gardner MD, Cowan RA, Boyle IT. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med 1988;68:825-34.
180. Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, et al. Treatment of hypercalcemia of malignancy with
181. Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983;74:401-6.
182. Thurlimann B, Waldburger R, Senn HJ, Thiebaud D. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Ann Oncol 1992;3:619-23.
183. Witte RS, Koeller J, Davis TE, Benson AB III, Durie BG, Lipton A, et al. Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. Arch Intern Med 1987; 147:937-9.
184. Ausili-Cefaro G, Capirci C, Crivellari D, Fontana V, Mandoliti G, Olmi P, et al. Radiation therapy vs radiation therapy + pamidronate (Aredia) in elderly patients with breast cancer and lytic bone metastases: a GROG-GIOGER randomized clinical trial. Rays 1999; 24 (Suppl 2):49-52.
185. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991;9:1397-402.
186. Berenson JR. The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. Rev Contemp Pharmacother 1998;9:195-203.
187. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200.
188. Berenson JR. Zoledronic acid in cancer patients with bone metastases: results of phase I and II trials. Semin Oncol 2001;28 [2 (Suppl 6)]:25-34.
189. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol 1998;101:280-6.
190. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 1994;5 (Suppl 7):S41-S44.
191. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2552-9.
192. Ford JF. Pamidronate in the treatment of bone metastases - the European experience. Br J Clin Pract Suppl 1996;87:3-4.
193. Daragon A, Humez C, Michot C, Le Loet X, Grosbois B, Pouyol F, et al. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur J Med 1993;2:449-52.
194. Delmas P, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, et al. Long-term effects of dichloromethylene diphosphonate (CL2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis and Relat Res 1982;4:163-8.
195. Diel IJ, Marschner N, Kindler M, Lange O, Untch M, Hurtz HJ, et al. Continuous oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases. J Clin Oncol (ASCO) 1999; abs 488.
196. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; i:146-9.
197. Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgstrom GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987;8 (Suppl 1):S53-S56.
198. Elomaa I, Blomqvist C, Porkka L, Holmstrom T, Taube T, Lamberg-Allardt C, et al. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 1988;42:111-16.
199. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 1994;74:2949-55.
200. Gomez-Pastrana E, Velasco JG, Requena A, Martinez-Salazar FJ, Martinez ME, Calero F. Clinical and biochemical valuation of clodronate in tumoral osteolysis by bone metastases of breast cancer. Prog Obstet Gynecol 1996;39:357-64.
201. Harris AL, Millward M, Tomkin K, Cantwell BM, Carmichael J, Wilson R, et al. Randomised trial of aminoglutethamide and hydrocortisone with and without disodium pamidronate (APD) in patients with advanced postmenopausal breast cancer and bone metastases. In Conference proceedings. Osteoclast inhibition in the management of malignancy related bone disorders. Seattle, WA: Hogrefe and Huber, 1993.
202. Heim ME, Clemens MR, Queirber W, Pecherstorfer M, Boewer C, Herold M, et al. Prospective randomised trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie 1995;18:439-48.
203. Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 1993;66:141-6.
204. Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:491-8.
205. Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, Hermans J, Kroon HM, Harinck HI, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987;ii:983-5.
206. Cleton FJ, Holten-Verzantvoort AT, Bijvoet OL. Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results Cancer Res 1989;116:73-8.
207. Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, Hermans J, Emmerik B, Dam FS, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991;27:544-9.
208. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-44.
209. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
210. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study. Acta Oncol 1996; 35 (Suppl 5):73-4.
211. Kraj M, Poglod R, Pawlikowski J, Maj S, Nasilowska B. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Acta Pol Pharm 2000;57:113-16.
212. Kraj M, Poglod R, Pawlikowski J, Maj S. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. Acta Haematol Pol 2000;31:379-89.
213. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74.
214. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52.
215. Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Sub-group and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 1994;87:725-9.
216. Theriault R. Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients. Br J Clin Pract Suppl 1996;87:8-12.
217. Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 1991;48:97-101.
218. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
219. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 19951;13:2427-30.
220. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001;88:701-7.
221. Hulin MT, Beuzeboc P, Mauriac L, Clavel M, Barbet N, Frenay M, et al. Double blind placebo controlled trial of oral clodronate in patients with bone metastases from breast cancer. Ann Oncol 1994;5 (Suppl 8):198.
222. Rosen LS, Gordon D, Tchekmedyian S, Hirsch V, Yanagihara R, Coleman RE, et al. Zoledronic acid significantly reduces skeletal related events in patients with bone metastases from solid tumours. Proc Am Soc Clin Oncol 2002; Abs1179.
223. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer 2001; 7:377-87.
224. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-68.
225. Abdulkadyrov KM, Bessmelisev SS. Bonefos efficacy in combined treatment of multiple myeloma. Terapeut Arkh 1993;65(12):70-2.
226. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, et al. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 1998;61:128-34.
227. Adami S, Mian M. Clodronate therapy and metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 1989; 116:s67-s72.
228. Arican A, Icli F, Akbulut H, Cakir M, Sencan O, Samur M, et al. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Med Oncol 1999;16:204-10.
229. Attardo-Parrinello G, Merlini G, Pavesi F, Crema F, Fiorentini ML, Ascari E. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Arch Intern Med 1987;147:1629-33.
230. Ausgabe A. Behandlung des hormonrefraktären Prostatakarzinomsmit schmerzhaften Knochenmetastasen. Urologe 1997;36:568.
231. Body JJ, Lichinitser MR, Diehl I, Schlosser K, Pfarr E, Cavalli F, et al. Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Proc Annu Meet Am Soc Clin Oncol 1999;18:A2222.
232. Cascinu S, Graziano F, Alessandroni P, Ligi M, Del Ferro E, Rossi D, et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 1998; 6:139-43.
233. Coleman RE, Purohit OP, Vinholes J, Zekri J. High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997; 80:1686-90.
234. Coleman RE, Houston SJ, Purohit OP, Rubens RD, Kandra A, Ford J. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. Eur J Cancer 1998; 34:820-4.
235. Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10:311-16.
236. Conte N, Di Virgilio R, Da Rin G, Roiter I, Pavan P, Legovini P, et al. Clodronate treatment increases serum osteocalcin in normocalcemic osteolytic bone metastases. Oncology 1991;48:54-7.
237. Costa L, Moreira C, Da Costa EB. Pamidronato dissódico (APD) no tatamento das metástases ósseas. [Disodium pamidronate (APD) in the treatment of bone metastases]. Acta Méd Port 1993;6:71-3.
238. Dearnaley DP, Sydes MR. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial. J Clin Oncol (ASCO) 2001;Abs 693.
239. Diel IJ, Lichinitser MR, Body JJ, Schlosser K, Moecks J, Cavalli F, et al. Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate. Eur J Cancer 1999;35 (Suppl 4):S83.
240. Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 1992;24:159-66.
241. Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 1996;32A:1166-70.
242. Ernst DS, MacDonald N, Paterson AHG, Jensen J, Brasher P, Bruera E. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992;7:4-11.
243. Ernst DS, Brasher P, Hagen N, Paterson AHG, MacDonald N, Bruera E. A randomised controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997;13:319-26.
244. Fernandez-Conde M, Alcover J, Aaron JE, Ordi J, Carretero P. Skeletal response to clodronate in prostate cancer with bone metastases. Am J Clin Oncol 1997;20:471-6.
245. Gessner U, Koeberle D, Thuerlimann B, Bacchus L, Horisberger B. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Support Care Cancer 2000;8:115-22.
246. Koeberle D, Bacchus L, Thurlimann B, Senn HJ. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomised double-blind trial. Support Care Cancer 1999;7:21-7.
247. Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993;29A(6):821-5.
248. Kylmala T, Taube T, Tammela T, Risteli L, Risteli J, Elomaa I. Concomitant IV and oral clodronate in the relief of bone pain - a double blind placebo controlled study in patients with prostate cancer. Br J Cancer 1697;76:939-42.
249. Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata R, et al. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 1994;5 (Suppl 7):s31-s35.
250. Lipton A. Zolendronate in the treatment of osteolytic bone metastases. Br J Clin Pract Suppl 1996;87:21.
251. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-6.
252. Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, et al. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990;8(1):23-30.
253. Moiseenko VM, Blinov NN, Semiglazov VV, Konstantinova MM, Trishkina EA. Randomised trial of two intravenous schedules of bonefos (clodronate) in patients with painful bone metastases. Vopr Onkol 1998;44:725-8.
254. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995;13:929-34.
255. Peest D, Deicher H, Fett W, Harms P, Braun HJ, Planker M, et al. Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy - a pilot study of the German Myeloma Treatment Group (GMTG). Eur J Cancer 1996;32A:2053-7.
256. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, et al. A double blind randomised study of oral clodronate in the treatment of bone metastases from tumours poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998; 17:213-17.
257. Poliakov PI, Larionova NA, Bychenkov OA, Moskin VG. An experience with combined therapy of radiation and Bonephos for osteolytic metastases of breast cancer. Vopr Onkol 1999;45:311-13.
258. Ringenberg QS, Ritch PS. Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. Clin Ther 1987;9:318-25.
259. Schiller JH, Rasmussen P, Benson AB, III, Witte RS, Bockman RS, Harvey HA, et al. Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med 1987;147:963-6.
260. Slaby J, Spicka I, Hulejová H, Spacek P, Cieslar P, Klener P. Effect of clodronate in patients with multiple myeloma. Cas Lék Cesk 1997;136:57-60.
261. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomised, prospective, double-blind, placebo-controlled study. J Urol 1989;141:85-7.
262. Strang P, Nilsson S, Brandstedt S, Sehlin J, Borghede G, Varenhorst E, et al. The analgesic effect of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997;17:4717-22.
263. Taube T, Elomaa I, Blomqvist C, Beneton MN, Kanis JA. Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study. Eur J Cancer 1993;29A:1677-81.
264. Taube T, Kylmala T, Lamberg-Allardt C, Tammela T, Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer 1994:30A:751-8.
265. Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000;65:331-6.
266. Thurlimann B, Morant R, Jungi WF, Radziwill AJ. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose effect study. Support Care Cancer 1994;2:61-5.
267. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996;73:1089-95.
268. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. An Oncol 1997;8:1243-50.
269. Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. Br J Cancer 1999; 80:221-8.
270. Zhang L, Guan Z, He Y. Randomised comparative clinical trial of treatment of bone metastatic diseases by infusion of palidronate and clodronate. Chin J Cancer 1997;16:430-2.
271. Zhang J, Chu Y, Xie S. Treatment of metastatic bone pain with Bonin either alone or combined with chemotherapy. Chin J Clin Oncol 1999; 26:762-4.
272. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metatases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-63.
273. Holten-Verzantvoort AT, Hermans J, Beex LV, Blijham G, Cleton FJ, Eck-Smit BC, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996;32A:450-4.
274. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7.
275. Mardiak J, Bohunicky L, Chovanec J, Salek T, Koza I. Adjuvant clodronate therapy in patients with locally advanced breast cancer - long-term results of a double blind randomised trial. Neoplasma 2000;47:177-80.
276. Powles T, Paterson S, Kanis JA, McCloskey EV, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-24.
277. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce skeletal metastases in node positive breast cancer. J Clin Oncol 2001;19:10-17.
278. Smith MR, McGoven FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen depravation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
279. Diel IJ, Solomayer EF, Goerner R, Gollan C, Wallweiner D, Bastea G. Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases. J Clin Oncol (ASCO) 1997; Abs 461.
280. Powles T, Tidy A, Ashley S, Kanis J, Paterson AD. Clodronate decreases the incidence of bone metastases in patients with advanced or metastatic breast cancer but no clinical evidence of bone metastases. Br J Cancer 1995;71 (Suppl 24):15.
281. Powles T, McCloskey E, Paterson AH, Ashley S, Tidy A, Kanis J. Oral clodronate will reduce the loss of bone mineral density in women with primary breast cancer. J Clin Oncol (ASCO) 1997; Abs 460.
282. Powles T, Paterson AH, Nevantaus A, Legault S, Pajunen M, Tidy A, et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. J Clin Oncol (ASCO) 1998;Abs 468.
283. Powles T, Paterson S, Ashley S, Rosenqvist K, Tidy A, Nevantaus A, et al. A placebo controlled trial of clodronate for prevention of bone metastases in patients with primary operable breast cancer. Bone 2000;26 (3 Suppl):42S.
284. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. No reduction of bone metastases with adjuvent clodronate treatment in node-positive breast cancer patients. J Clin Oncol (ASCO), 1999; Abs 570.
285. Vehmanen L, Saarto T, Blomqvist C, Virkkunen P, Elomaa I. The effect of adjuvant clodronate on bone mineral density (BMD) in pre- and postmenopausal breast cancer patients. A randomized 5 year follow-up study. Eur J Cancer 1999;35 (Suppl 4):S159.
286. Powles T, McCloskey E, Paterson AH, Ashley S, Tidy A, Nevantaus A, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Nat Cancer Inst 1998;90:704-8.
287. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C. Long-term impact of chemotherapy induced ovarian failure on bone mineral density (BMD) in pre-menopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37:2373-8.
288. Saarto T, Vehmanen L, Elomaa I, Valimaki M, Makela P, Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001;84:1047-51.
289. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomised study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341-7.
290. Blay JY. Traitement adjuvant du cancer du sein localisé à haut risque de rechute: et maintenant les diphosphonates. Bull Cancer 1998;85:741.
291. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000;18:3925-35.
292. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999;5:3914-19.
293. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Nat Cancer Inst 2001;93:178-93.
294. Lokeshwar BL. MMP inhibition in prostate cancer. Ann N Y Acad Sci 1999;878:271-89.
295. Rutqvist LE. Randomized adjuvant breast cancer trials in Sweden. Cancer 1994;74 (3 Suppl):I156-9.
296. Smith TJ, Hillner BE. Clodronate reduced the incidence of bony and visceral metastases in patients with breast cancer and tumour cells in the bone marrow. Evid Based Med 1999;4:43.
297. Wolff AC, Abeloff MD. Adjuvant systemic management of early stage carcinoma of the breast. Surg Oncol 1999;8:93-101.
298. Strong KM, McPherson ML. Pamidronate. Am J Hospice Palliative Care 1998;15:54-5.
299. Beijnen JH, Koks CHW. Didronel IV met 100% korting (I). Pharm Weekbl 1990;125:383-4.
300. Kao G. Pamidronate and metastatic breast disease. N Engl J Med 1997;336:1609.
301. Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992;26:1262-9.
302. Madeline I, Berton B, Paubel P, Faure P. Impact budgétaire des anticancéreux et des médicaments des thérapeutiques adjuvantes depuis 10 ans à l'hôpital Saint-Louis. Haematologie 1999;5 (Suppl 1):89-91.
303. Anon., Multiple myeloma: QALY gains from optimal therapy. Drugs Ther Perspect 2002;16:12-16.
304. Consumers Association. Treating cancer associated hypercalcaemia. Drug Ther Bull 1990;28:85-7.
305. Balducci L. Cost effectiveness of pamidronate in the treatment of breast cancer in the metastatic and adjuvant setting [meeting abstract 1599]. Proc Am Soc Clin Oncol 1998;17:415a.
306. Bruce NJ, McCloskey EV, Kanis JA, Guest JF. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol 1999;104:358-64.
307. Coyte PC, Dobrow MJ, Broadfield L. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics 2001;19:845-54.
308. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001;9:545-51.
309. Guignard E, Dardenne J, Pelc A, et al. Economic assessment of clodronate in the preventive treatment of bone resorption in patients with metastatic breast cancer. Eur J Cancer 1997; 33(Suppl 9):S25.
310. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9.
311. Marchetti N, Liberato NL, Tamburlini A, Barosi G. Cost-effectiveness of pamidronate in breast cancer patients with skeletal metastases. J Med Decis Making 2000;20:477.
312. Puolijoki H, Liippo K. Symptomatic hypercalcaemia in lung cancer. Respir Med 1992; 86:359-60.
313. Elomaa I. Use of bisphosphonates in skeletal metastases. Acta Oncol 2001;39:445-54.
314. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998;78:157-69.
315. Gallacher SJ. Formulary management of drugs for cancer-associated hypercalcaemia. Pharmacoeconomics 1996;9:39-50.
316. Hillner BE. The role of bisphosphonates in metastatic breast cancer. Semin Radiat Oncol 2000;10:250-3.
317. McCloskey EV, Libretto SE. Use of bisphosphonates in the treatment of multiple myeloma. Hematology 1998;3:291-8.
318. McCloskey E, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001;61:1253-74.
319. Pereira J, Mancini I, Walker P. The role of bisphosphonates in malignant bone pain: a review. J Palliative Care 1998;14:25-36.
320. Gurney H, Grill V, Martin TJ. Parathyroid hormone related protein and response to pamidronate in tumor induced hypercalcaemia. Lancet 1993;341:1611-13.
321. Walls J, Ratcliffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 1994;70:169-72.
322. Kukreja SC, Shevrin DH, Wimbiscus SA, Ebeling PR, Danks JA, Rodda CP, et al. Antibodies to parathyroid hormone related protein lower serum calcium in athymic mouse models of malignancy associated hypercalcaemia due to human tumours. J Clin Invest 1988;82:1798-802.
323. Bayne MC, Illidge TM. Hypercalcaemia, parathyroid hormone-related protein and malignancy. Clin Oncol 2001;13:377.
324. Body JJ, Louviaux I, Dumon JC. Decreased efficacy of bisphosphonates for recurrences of tumour-induced hypercalcaemia - mechanisms and influence of tumour type. J Clin Oncol. (ASCO) 1998; Abs 169.
325. Joshua F, Epstein M, Major G. Bisphosphonate resistance in Paget's disease. Bone 2000; 27 (4 Suppl):24S.
326. Ali SM, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:3434-7.
327. Krempien B, Manegold C. Prophylactic treatment of skeletal metastases, tumour-induced osteolysis and hypercalcaemia in rats with the bisphosphonate CL2MBP. Cancer 1993;72:91-8.
328. Goldhirsch A, Gelber RD, Price KN, Castiglione M, Coates AS, Rudenstam CM, et al. Effect of systemic adjuvant treatment on the first sites of breast cancer relapse. Lancet 1994;343:377-81.
329. Krempien B, Wingen F, Eichmann T, Muller M, Schmahl D. Protective effects of prophylactic treatment with APD on the development of tumour osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 1988;45:41-6.
330. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomised clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have oestrogen-receptor-positive tumours. N Engl J Med 1989; 320(8):479-84.
331. Braun S, Cevalti BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001;19:1468-75.
332. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323:1300-3.
333. Rawlings M. Completed technology appraisals 2000/2001. London: National Institute for Clinical Excellence, 2001.
334. Durie, BGM, Multiple myeloma. Oncol Spectrums 2001;1:113.
335. Wisloff F, Gulbrandsen N, Nord E. Therapeutic options in the treatment of multiple myeloma. Pharmacoeconomics 1999;16:329-41.